苑东生物(688513) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥322,179,501.72, representing a year-over-year increase of 17.27%[6] - Net profit attributable to shareholders for Q3 2022 was ¥60,856,356.20, showing a decrease of 11.46% compared to the same period last year[6] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥38,517,219.50, an increase of 21.54% year-over-year[6] - Total operating revenue for the first three quarters of 2022 reached ¥897,590,018.32, an increase of 16.1% compared to ¥773,436,181.18 in the same period of 2021[24] - Net profit for the first three quarters of 2022 was ¥195,492,474.81, representing a growth of 5.5% from ¥186,075,903.15 in 2021[31] - Basic earnings per share for Q3 2022 were ¥0.51, down 10.53% compared to the same period last year[10] - Basic earnings per share for the first three quarters of 2022 were ¥1.63, compared to ¥1.55 in the same period of 2021[33] Research and Development - R&D investment totaled ¥75,772,263.90 in Q3 2022, up 41.55% from the previous year, accounting for 23.52% of revenue[10] - Research and development expenses for the first three quarters of 2022 amounted to ¥165,078,988.64, up 11.6% from ¥147,822,178.55 in the previous year[27] Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥3,003,472,092.39, an increase of 8.22% from the end of the previous year[10] - The company's total current liabilities increased to ¥563,972,583.20 from ¥432,458,963.97, which is an increase of approximately 30.4%[22] - The total liabilities as of the end of the reporting period were ¥609,933,988.70, an increase from ¥483,601,755.82 in the previous year[24] - The total equity attributable to shareholders reached ¥2,393,538,103.69, up from ¥2,291,664,728.59 in 2021[24] Cash Flow - The company reported a net cash flow from operating activities of ¥141,346,062.05 for the year-to-date period, a decrease of 2.09% year-over-year[10] - Cash inflow from operating activities totaled ¥981,016,081.53 in the first three quarters of 2022, an increase from ¥909,989,358.80 in 2021[36] - The net cash flow from operating activities was $141,346,062.05, a decrease from $144,363,177.82 in the previous period[37] - Cash outflow from investing activities totaled $2,310,797,186.24, down from $3,297,696,338.54 year-over-year[37] - The net cash flow from investing activities was -$673,657,053.10, an improvement from -$943,287,000.18 in the prior period[37] - Cash inflow from financing activities amounted to $147,373,150.35, compared to $10,000,000.00 previously[37] - The net cash flow from financing activities was $52,188,019.78, a recovery from -$76,362,236.06 in the last period[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,138[13] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 2.57%, a decrease of 0.54 percentage points year-over-year[10] - Government subsidies recognized in Q3 2022 amounted to ¥17,921,133.78, contributing to non-recurring gains[10] - The company's cash and cash equivalents decreased to ¥559,858,478.86 from ¥1,050,695,494.02 year-over-year, representing a decline of approximately 46.8%[19] - The trading financial assets increased significantly to ¥766,076,763.67 from ¥453,840,935.17, marking an increase of approximately 68.8%[19] - Accounts receivable rose to ¥137,554,068.67 from ¥112,427,878.56, reflecting an increase of about 22.3%[19] - The company's inventory increased to ¥123,781,058.87 from ¥103,682,790.76, representing an increase of about 19.4%[19] - The company's long-term equity investments were recorded at ¥98,030,208.71, with no previous year data available for comparison[22] - The company reported a significant increase in other non-current financial assets, totaling ¥22,000,000.00, with no previous year data available[22] Business Developments - The company has not reported any significant new product developments or market expansions during the reporting period[16] - There were no significant mergers or acquisitions disclosed in the third quarter report[16]